Topic: drug reimbursement
Merck’s Keytruda may be pressuring BMS’ Opdivo in kidney cancer in the U.S. But in England, cost watchdogs won’t be giving it the chance.
It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.
As JPM kicks into gear, Novartis CEO Vas Narasimhan and British health officials unveiled a new access agreement on inclisiran.
Patients with small cell lung cancer don’t have a lot of options. But that fact didn’t convince NICE to foot the bill for Roche's Tecentriq.
Astellas buys gene therapy player Audentes for $3 billion. Keytruda and Opdivo fail to win coverage in China. Hanmi inks I-O deal with Rapt.
It’s a familiar scene in the race onto China’s national reimbursement list: Drugmakers cut prices by an average 60.7% to win coverage.
Rival PARP inhibitors by GSK and AstraZeneca-Merck already have their own NICE backing, though neither of the three is on routine coverage.
Vertex hasn't been able to reach a deal for cystic fibrosis drug access in England, but in neighbor Scotland, the company has struck a five-year agreement.
New CMS rules have removed some restrictions on healthcare providers that could in turn boost uptake of Gilead's and Novartis' CAR-T drugs.
Contradicting analysts' observations, Novartis CEO dubbed Zolgensma “one of the most successful launches from an access standpoint in rare diseases.”